- Home
- CNDT vs ITOS Comparison
CNDT vs ITOS Comparison
Compare CNDT & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNDT
- ITOS
- Stock Information
- Founded
- CNDT 2016
- ITOS 2011
- Country
- CNDT United States
- ITOS United States
- Employees
- CNDT N/A
- ITOS N/A
- Industry
- CNDT Business Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNDT Consumer Discretionary
- ITOS Health Care
- Exchange
- CNDT Nasdaq
- ITOS Nasdaq
- Market Cap
- CNDT 381.9M
- ITOS 381.2M
- IPO Year
- CNDT N/A
- ITOS 2020
- Fundamental
- Price
- CNDT $2.79
- ITOS $9.99
- Analyst Decision
- CNDT
- ITOS Hold
- Analyst Count
- CNDT 0
- ITOS 6
- Target Price
- CNDT N/A
- ITOS $10.60
- AVG Volume (30 Days)
- CNDT 1.5M
- ITOS 923.4K
- Earning Date
- CNDT 08-06-2025
- ITOS 08-07-2025
- Dividend Yield
- CNDT N/A
- ITOS N/A
- EPS Growth
- CNDT N/A
- ITOS N/A
- EPS
- CNDT 1.54
- ITOS N/A
- Revenue
- CNDT $3,186,000,000.00
- ITOS $35,000,000.00
- Revenue This Year
- CNDT N/A
- ITOS N/A
- Revenue Next Year
- CNDT $2.53
- ITOS N/A
- P/E Ratio
- CNDT $1.81
- ITOS N/A
- Revenue Growth
- CNDT N/A
- ITOS 177.89
- 52 Week Low
- CNDT $1.90
- ITOS $4.80
- 52 Week High
- CNDT $4.90
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- CNDT 55.04
- ITOS 62.99
- Support Level
- CNDT $2.57
- ITOS $9.93
- Resistance Level
- CNDT $2.71
- ITOS $10.20
- Average True Range (ATR)
- CNDT 0.11
- ITOS 0.15
- MACD
- CNDT -0.02
- ITOS -0.12
- Stochastic Oscillator
- CNDT 26.40
- ITOS 24.10
About CNDT Conduent Incorporated
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.